Brief: Redwood Pharma: Supplementary Analyses To Topline Phase II Results Reveal Additional RP101 Clinical Strengths

Redwood Pharma AB

29/12/2020 07:09

Dec 29 (Reuters) - Redwood Pharma AB  REDWPH.TE :
    * SUPPLEMENTARY ANALYSES TO TOPLINE PHASE II RESULTS REVEAL
ADDITIONAL RP101 CLINICAL STRENGTHS
    * RP101 DEMONSTRATES TREATMENT DIFFERENCE VERSUS CONTROL
(INTELLIGEL VEHICLE) IN INFERIOR CORNEAL STAINING WITH ROBUST
AND SIGNIFICANT IMPROVEMENT
    * FOLLOW-ON ANALYSIS COMPLEMENTING ORIGINAL TRIAL PROTOCOL
REVEALS
FURTHER KEY EVIDENCE OF CANDIDATE'S THERAPEUTIC STRENGTHS
    * TOPLINE ANALYSIS OF RP101 SHOWED SIGNIFICANT IMPROVEMENT
OVER
COURSE OF 90-DAY TRIAL OF PRE-DEFINED PRIMARY AND SECONDARY
ENDPOINTS
    * NEW FINDINGS SHOWED THAT RP101 DEMONSTRATED STATISTICALLY
SIGNIFICANT TREATMENT EFFECT ON CORNEAL DAMAGE ASSESSED BY
CORNEAL STAINING, AND MORE SPECIFICALLY ON INFERIOR PART OF
CORNEA (ONE OF FIVE ZONES ON CORNEA THAT IN AGGREGATE COMPRISE
TOTAL CORNEAL STAINING ENDPOINT)

Source text for Eikon:  ID:nWkrb6mXMx 
Further company coverage:  REDWPH.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))